Relmada Therapeutics, Inc. RLMD Common stock, shares authorized (in shares)
Common stock, shares authorized (in shares) at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s common stock, shares authorized (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s common stock, shares authorized (in shares)?
- Relmada Therapeutics, Inc. (RLMD) reported common stock, shares authorized (in shares) of $150M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s common stock, shares authorized (in shares) changed year-over-year?
- Relmada Therapeutics, Inc.'s common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $150M to $150M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s common stock, shares authorized (in shares)?
- Over 5 years (2020 to 2025), Relmada Therapeutics, Inc.'s common stock, shares authorized (in shares) has grown at a 24.6% compound annual growth rate (CAGR), from $50M to $150M.